Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03787069
Other study ID # IRD_IRB_2017_07_002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 20, 2017
Est. completion date July 20, 2018

Study information

Verified date December 2018
Source Indus Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the mean hemodynamic responses post-intubation in patients given intravenous lignocaine pre-intubation as compared to a placebo pre-intubation in patients undergoing laryngoscopy surgery


Description:

After identifying the candidate, details will be carefully discussed with the subject. The subject (or, when necessary, the parent or legal guardian if the subject is younger than 18 years of age or under guardianship) will be read the approved protocol consent form. Patients who have given informed consent to participate in the study will be randomized into one of the two study arms one day before the procedure. The study team present will open the sealed envelopes provided by the Indus Hospital Research Center's Clinical Research Unit (CRU) that provides the study arm allocation. The envelopes will follow the SNOSE protocol.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date July 20, 2018
Est. primary completion date July 20, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- ASA I and II

- Age 20-60 years

- Mallampatti , II

- All surgeries are done under GA

- Both genders

- Those patients giving informed consent

Exclusion Criteria:

- Difficult airway assessed during pre-op anaesthesia assessment

- Unanticipated difficult airway based on the previous history of difficult intubation

- BMI >30,

- Micrognathia and microglossia based on pre-op anaesthesia assessment,

- Diabetic patient with autonomic dysfunction liver disease, cardiovascular disease, pheochromocytoma, Cushing syndrome

- Patients who do not give informed consent

Study Design


Related Conditions & MeSH terms

  • Hemodynamic Stability Post Intubation in Laryngoscopy Surgery

Intervention

Drug:
iv Lignocaine vs placebo
Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V

Locations

Country Name City State
Pakistan The Indus Hospital Karachi Sind

Sponsors (1)

Lead Sponsor Collaborator
Indus Hospital

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary MAP mean arterial pressure post-intubation 3 minutes to 10 minutes
Primary Pulse Heart rate post-intubation 3 minutes to 10 minutes